Bionano Genomics, Inc.
Bionano Genomics, Inc. (BNGO) Financial Performance & Income Statement Overview
Analyze Bionano Genomics, Inc. (BNGO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Bionano Genomics, Inc. (BNGO) Income Statement & Financial Overview
Review Bionano Genomics, Inc. BNGO income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $6.46M | $8.16M | $6.07M | $7.77M |
| Cost of Revenue | $3.05M | $4.75M | $14.52M | $5.19M |
| Gross Profit | $3.40M | $3.42M | -$8.45M | $2.58M |
| Gross Profit Ratio | $0.53 | $0.42 | -$1.39 | $0.33 |
| R&D Expenses | $2.37M | $3.47M | $4.72M | $6.83M |
| SG&A Expenses | $9.03M | $11.75M | $9.46M | $11.56M |
| Operating Expenses | $11.40M | $15.36M | $35.45M | $19.60M |
| Total Costs & Expenses | $14.46M | $20.10M | $49.97M | $24.79M |
| Interest Income | $290000.00 | $225000.00 | $376000.00 | $457000.00 |
| Interest Expense | $85000.00 | $27000.00 | $68000.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $2.45M | $5.68M | $3.04M |
| EBITDA | -$8.46M | -$17.65M | -$38.47M | -$12.71M |
| EBITDA Ratio | -$1.31 | -$2.16 | -$6.34 | -$1.64 |
| Operating Income | -$8.46M | -$11.94M | -$43.90M | -$17.02M |
| Operating Income Ratio | -$1.31 | -$1.46 | -$7.23 | -$2.19 |
| Other Income/Expenses (Net) | $5.37M | -$8.18M | -$321000.00 | $820000.00 |
| Income Before Tax | -$3.10M | -$20.12M | -$44.22M | -$16.20M |
| Income Before Tax Ratio | -$0.48 | -$2.47 | -$7.28 | -$2.08 |
| Income Tax Expense | -$7000.00 | $1000.00 | $24000.00 | $26000.00 |
| Net Income | -$3.10M | -$20.13M | -$44.25M | -$16.22M |
| Net Income Ratio | -$0.48 | -$2.47 | -$7.29 | -$2.09 |
| EPS | -$1.15 | -$647.40 | -$1800.60 | -$864.00 |
| Diluted EPS | -$1.15 | -$647.40 | -$1800.60 | -$864.00 |
| Weighted Avg Shares Outstanding | $2.69M | $1.90M | $1.46M | $1.15M |
| Weighted Avg Shares Outstanding (Diluted) | $2.69M | $1.90M | $1.46M | $1.15M |
The company's financials show resilient growth, with revenue advancing from $7.77M in Q2 2024 to $6.46M in Q1 2025. Gross profit remained healthy with margins at 53% in Q1 2025 compared to 33% in Q2 2024. Operating income hit -$8.46M last quarter, sustaining a consistent -131% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$8.46M. Net income rose to -$3.10M, while earnings per share reached -$1.15. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan